A retrospective clinical trial analyzed 20 RET fusion NSCLC patients who were resistant to selpercatinib and pralsetinib, and they found 15% MET amplification and 10% G810C/S mutation. The gene discussed is RET; the disease is non-small cell lung carcinoma.